Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBP siRNA
- Development stage
- Preclinical
- Lead developer
- Comanche Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
CBP siRNA is a research-stage small interfering RNA (siRNA) designed to silence the expression of the CREB-binding protein (CBP), a key transcriptional coactivator and histone acetyltransferase. By targeting the mRNA of CBP for degradation, this compound reduces the cellular levels of the protein, thereby inhibiting its role in gene transcription and epigenetic modification. In preclinical research, CBP siRNA has been utilized as an experimental tool to investigate the pathophysiology of neuropathic pain and the progression of prostate cancer. For example, intrathecal administration in rat models of spared nerve injury has shown that knocking down CBP in the spinal cord can inhibit mechanical allodynia. In oncology research, it has been used to study the differential roles of CBP and its paralog p300 in cell survival and invasion. It is primarily produced as a custom research reagent and is not currently associated with a commercial clinical development program.
- Other names
- CREB-binding protein siRNACREBBP siRNA
02
Targets
CREBBP (CREB-binding protein)
Beyond the preview
Go deeper on CBP siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBP siRNA.